Emerging Treatments in Recurrent and Metastatic Colorectal Cancer

Metastatic colorectal cancer is a prevalent disease for which many new therapies have been developed over the past decade. Currently, standard of care chemotherapeutic regimens for metastatic colorectal cancer include doublet cytotoxic chemotherapy with or without the anti–vascular endothelial growth factor monoclonal antibody bevacizumab, anti-epidermal growth factor receptor monoclonal antibodies such as cetuximab and panitumumab with or without chemotherapy, and single-agent cytotoxic chemotherapy or targeted therapy for those patients intolerant of combination regimens. Recent studies have investigated the efficacy of triplet cytotoxic chemotherapeutic regimens, bevacizumab in combination with chemotherapy beyond first-line therapy disease progression, dual anti-vascular endothelial growth factor and anti-epidermal growth factor receptor antibody therapy, and the more novel agents ziv-aflibercept and regorafenib for the treatment of metastatic colorectal cancer. Furthermore, molecular profiling of colorectal cancer has identified a number of genetic alterations for which targeted therapies are currently being developed. Optimal drug combinations and treatment sequences have yet to be defined, but an expanding armamentarium of therapies with which to treat colorectal cancer offers a promising future.

Target Audience

This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Differentiate the various treatment options for metastatic CRC (mCRC)
  • Appraise the recent clinical trial results of anti-EGFR and anti-VEGF therapies for determining optimal drug combinations and treatment sequences for mCRC
  • Describe the two proven examples of genetic alterations leading to personalized therapy for patients with mCRC
Additional information
Supporters: 

Supported by educational grants from sanofi-aventis U.S. and Regeneron Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.; Genentech, USA; and Lilly USA, LLC.

Course summary
Available credit: 
  • 1.25 Participation
  • 1.25 Nurse
  • 1.25 Pharmacist
  • 1.25 Physician
Course opens: 
10/04/2013
Course expires: 
08/31/2014
Cost:
$0.00

Kristen Keon Ciombor, MD, MSCI
Division of Medical Oncology
Department of Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Tanios Bekaii-Saab, MD
Division of Medical Oncology
Department of Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Available Credit

  • 1.25 Participation
  • 1.25 Nurse
  • 1.25 Pharmacist
  • 1.25 Physician

Accreditation Period

Course opens: 
10/04/2013
Course expires: 
08/31/2014

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing